Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Source : https://onlinelibrary.wiley.com/doi/10.1111/bjh.17541

Bortezomib- and lenalidomide-based therapies have become standard front-line treatment for multiple myeloma (MM),1 resulting in many patients being refractory to bortezomib or lenalidomide at first relapse.2, 3 This may negatively impact the efficacy of later lines of therapy (LOT)4 and makes optimal sequencing of MM therapies challenging.